Mantle cell lymphoma
Not recruitingStudy of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant
Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant
- Disease:Mantle cell lymphoma
- Substances:RituximabZanubrutinib+1
Spain- Participants:18–64 years · 65+ years
- Substances:Rituximab
- Sponsor:BeOne Medicines AG









